RxDoctor Payments Data

Emily Buchanan

Family · Morristown, TNNPI 1477171700

Payments from drug & device makers

$5,050in general payments, 2019–2025

Across 315 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$986
  • Novo Nordisk$664
  • GSK$550
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$239
  • Novartis$228
  • Sumitomo Pharma America, Inc.$183
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,050 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,285
Medicare patients
129
Services billed
1,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$52,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$49,337
FarxigaDapagliflozin Propanediol32$32,680
Nurtec OdtRimegepant Sulfate13$27,614
GemtesaVibegron26$24,205
TrulicityDulaglutide20$21,662
EliquisApixaban22$20,771
JardianceEmpagliflozin18$18,771
RybelsusSemaglutide17$17,648
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$15,733
MounjaroTirzepatide14$15,279
LinzessLinaclotide17$11,928
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,334
TrintellixVortioxetine Hydrobromide13$7,198
Spiriva RespimatTiotropium Bromide12$7,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$664$70,64766 claims
GSKTrelegy Ellipta$550$49,33766 claims
AstraZenecaFarxiga, Breztri Aerosphere$106$48,41354 claims
PfizerNurtec Odt, Eliquis$148$48,38535 claims
Lilly USA, LLCTrulicity, Mounjaro$109$36,94134 claims
Boehringer IngelheimJardiance, Spiriva Respimat$91$25,94030 claims
Sumitomo Pharma America, Inc.Gemtesa$183$24,20526 claims
AbbVieLinzess$986$11,92817 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$7,19813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Morristown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →